generation run 2026-04-28
69 min completedmodel pipeline-v5plan not recordedrun/74baf7af…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
none raised on this run
Reproduce
- inputs
- 37 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
26 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | OpenAlex | diazepam benzodiazepine pharmacology | 10 | 2 | Landmark papers on receptor discovery and subunit distribution; highest citation counts |
| 2 | PubMed | benzodiazepine GABA-A receptor subunit selectivity diazepam alpha binding affinity | 8 | 3 | Direct data on diazepam subunit selectivity and binding mechanism at GABA-A receptors |
| 3 | PubMed | diazepam pharmacokinetics bioavailability half-life metabolism humans | 10 | 0 | — |
| 4 | PubChem | diazepam | 1 | 1 | Primary database lookup to verify chemical identity data from brief |
| 5 | PubMed | PMID 918669 | 1 | — | — |
| 6 | PubMed | diazepam pharmacology GABA-A receptor mechanism binding | 10 | 0 | — |
| 7 | PubMed | diazepam opioid interaction respiratory depression combined overdose death | 8 | 2 | Quantified mortality risk for opioid-benzodiazepine combination; directly supports interaction severity flagging |
| 8 | PubMed | diazepam metabolism CYP2C19 CYP3A4 desmethyldiazepam active metabolite | 3 | 3 | These directly characterize CYP2C19 and CYP3A4 involvement in diazepam metabolism |
| 9 | ClinicalTrials.gov | diazepam | 10 | 1 | Only trial with diazepam as primary intervention found in first search |
| 10 | PubMed | benzodiazepine tolerance mechanism GABA-A receptor downregulation subunit expression | 7 | 5 | Mechanistic basis of tolerance; relevant to tolerance section of article |
| 11 | PubMed | benzodiazepine dependence withdrawal syndrome physical addiction benzodiazepine | 9 | 4 | Clinical characterization of withdrawal syndrome and dependence mechanisms |
| 12 | PubMed | benzodiazepine tolerance GABA-A receptor downregulation mechanism | 7 | — | — |
| 13 | PubMed | PMID 362051 - Clinical pharmacokinetics of diazepam | 1 | — | — |
| 14 | PubMed | diazepam status epilepticus seizure treatment rescue | 6 | — | — |
| 15 | WebSearch | diazepam legal status Schedule IV DEA UK international | 10 | — | — |
| 16 | WebSearch | diazepam SMILES DrugBank melting point solubility physical properties | 10 | — | — |
| 17 | PubMed | benzodiazepine GABA-A subunit alpha1 alpha2 alpha3 alpha5 selective | 5 | — | — |
| 18 | PubMed | PMID 24007886 - History of benzodiazepines | 1 | — | — |
| 19 | WebSearch | diazepam Sternbach synthesis discovery 1963 Valium history benzodiazepine Roche | 10 | — | — |
| 20 | WebSearch | diazepam pharmacokinetics half-life oral bioavailability protein binding | 10 | — | — |
| 21 | Multiple · absence | Verify seed data against confirmed sources | 0 | — | — |
| 22 | Multiple PubMed/OpenAlex sources · absence | Compile pharmacokinetics, receptor data, history, legal status | 0 | — | — |
| 23 | PubMed | benzodiazepine overdose treatment flumazenil reversal emergency management | 6 | 3 | Key flumazenil reversal data for harm reduction and overdose management sections |
| 24 | PubMed | diazepam neonatal floppy infant syndrome pregnancy teratogenicity | 1 | 1 | Comprehensive review of teratogenicity and neonatal effects of diazepam/benzodiazepines |
| 25 | PubMed | PMID 33368617 - reappraisal acute benzodiazepines anterograde amnesia | 1 | — | — |
| 26 | PubMed | diazepam alcohol ethanol combined pharmacokinetic pharmacodynamic interaction clinical study | 5 | 3 | Controlled human studies of diazepam-alcohol pharmacodynamic interaction |
115 claims by section — every cited sentence, checked against its source
safety42 · 31 ok
Claim in safety — inconclusiveinconclusiveworking →
Diazepam produces additive-to-synergistic CNS and respiratory depression when combined with opioids, alcohol, or other CNS depressantssupported
The mortality rate in co-administration of both medications is 10 times higher than those taking only opioids. pmid:33264528
Diazepam produces additive-to-synergistic CNS and respiratory depression when combined with opioids, alcohol, or other CNS depressantssupported
Benzodiazepine-opioid combination therapy is potentially harmful due to the risk of synergistic respiratory depression. j.ajem.2016.11.054
Benzodiazepines are present in approximately 30% of opioid overdose deathssupported
Benzodiazepines are involved in 30% of opioid overdoses. pmid:33264528
Mortality with opioid–benzodiazepine co-administration is approximately 10 times higher than with opioids alone.supported
The mortality rate in co-administration of both medications is 10 times higher than those taking only opioids. pmid:33264528
In a multicenter RCT (n = 326), flumazenil achieved successful reversal in 77% of benzodiazepine-positive overdose patients versus 16% with placebosupported
Among benzodiazepine-positive patients, 77% given flumazenil vs 16% given placebo attained successful response. pmid:1286503
The reversal effect is short-acting (median duration ~90 minutes), requiring monitoring for resedation.supported
Median effect of flumazenil lasted 90 minutes. 61% of initial responders became resedated. pmid:1286503
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Flumazenil titrated IV (0.1–0.3 mg increments) only in cases of isolated benzodiazepine overdose in non-dependent patients.supported
Incremental intravenous bolus injections of flumazenil 0.1-0.3 mg are the most effective in diagnosis and treatment of pure benzodiazepine overdose. pmid:9306053
Claim in safety — inconclusiveinconclusiveworking →
Epidemiological data identify benzodiazepine exposure density as an independent risk factor for cognitive impairment in middle-aged and older patients, and observational studies report associations between chronic benzodiazepine use and increased dementia risk.supported
BZD exposure density was an independent risk factor of cognitive impairment in middle-aged and older patients with chronic insomnia. Long-term use of BZDs may cause cognitive impairment and increase risk for dementia in older patients. fnhum.2021.775144
Epidemiological data identify benzodiazepine exposure density as an independent risk factor for cognitive impairment in middle-aged and older patients, and observational studies report associations between chronic benzodiazepine use and increased dementia risk.supported
Investigated whether BZD use was related to developing mild cognitive impairment or dementia in cognitively normal older adults in the community. s1041610223000455
Late third-trimester diazepam use and exposure during labor are associated with floppy infant syndrome — neonatal sedation, hypotonia, reluctance to suck, apnoeic spells, cyanosis, and impaired metabolic responses to cold stresssupported
Late third trimester exposure to diazepam associated with floppy infant syndrome and neonatal withdrawal symptoms: sedation, hypotonia, reluctance to suck, apnoeic spells, cyanosis. pmid:7881198
Claim in safety — inconclusiveinconclusiveworking →
Diazepam is excreted into breast milk at low levels.supported
Diazepam excreted in breast milk. pmid:7881198
Diazepam produces anterograde amnesia that impairs the formation of new memories during intoxicationsupported
Acute administration of benzodiazepines is considered a pharmacological model of general organic anterograde amnesias. hup.2774
Tolerance to anticonvulsant effects develops within 10–14 dayssupported
10-14 days treatment with increasing doses of diazepam resulted in anticonvulsant tolerance. prp2.416
Claim in safety — inconclusiveinconclusiveworking →
The mechanism involves three convergent processes: L-VGCC-mediated downregulation of surface α1-containing GABA-A receptors, transcriptional suppression of the α1 subunit gene, and epigenetic silencing via HDAC1/HDAC2 upregulation.supported
Persistent exposure of GABAA receptors to benzodiazepines produces uncoupling and downregulation of functional alpha1-containing GABAA receptors through two distinct mechanisms, both initiated by calcium influx through L-VGCCs. j.neulet.2025.138495
Claim in safety — inconclusiveinconclusiveworking →
The mechanism involves three convergent processes: L-VGCC-mediated downregulation of surface α1-containing GABA-A receptors, transcriptional suppression of the α1 subunit gene, and epigenetic silencing via HDAC1/HDAC2 upregulation.supported
Diazepam treatment induced uncoupling between GABA and benzodiazepine sites and produced selective transcriptional down-regulation of GABAA receptor alpha1 subunit gene through a mechanism dependent on L-type voltage-gated calcium channels. j.neulet.2020.134801
The mechanism involves three convergent processes: L-VGCC-mediated downregulation of surface α1-containing GABA-A receptors, transcriptional suppression of the α1 subunit gene, and epigenetic silencing via HDAC1/HDAC2 upregulation.supported
10-14 days treatment with increasing doses of diazepam resulted in anticonvulsant tolerance and decreased expression of the alpha1 GABAA receptor subunit mRNA and protein in frontal cortex. prp2.416
Physical dependence develops even at low therapeutic doses (10–20 mg/day equivalent) with long-term usesupported
Physical dependence is a risk associated with long-term use, even at therapeutic doses (10-20 mg of diazepam equivalent). pmid:1675689
High-dose users (mean 150 mg diazepam equivalents/day) develop severe dependencesupported
Data from 23 patients abusing high doses of benzodiazepines (mean 150 mg diazepam equivalents/day). pmid:2574193
The Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B) — a validated 22-item scale — was developed from benzodiazepine-dependent populations including diazepam userssupported
Data from 23 patients abusing high doses of benzodiazepines (mean 150 mg diazepam equivalents/day) and 40 long-term therapeutic users analyzed to develop the CIWA-B scale. pmid:2574193
Abrupt cessation after 21 days of continuous treatment produces measurable withdrawal within 24 hours in animal models.supported
Abrupt cessation of protracted once-daily administration of 2 mg/kg diazepam induced a withdrawal syndrome, measured by increased anxiety-like behavior 24 h after treatment cessation. j.brainresbull.2012.10.011
The dependence-related GABA-A receptor changes (α1 downregulation) correlate with withdrawal severity; receptor upregulation after discontinuation contributes to rebound excitability.supported
GABAA receptor downregulation pathway: (1) desensitization, (2) sequestration/uncoupling, (3) subunit polypeptide degradation, (4) repression of subunit gene expression. Correlates with tolerance and physical dependence on benzodiazepines. pmid:8894844
Claim in safety — inconclusiveinconclusiveworking →
The combination of diazepam with opioids produces synergistic respiratory depression through pharmacodynamically independent mechanisms: opioid μ-receptor agonism suppresses brainstem respiratory centers while diazepam enhances GABAergic inhibition of the same circuitssupported
Benzodiazepine-opioid combination therapy is potentially harmful due to the risk of synergistic respiratory depression. j.ajem.2016.11.054
Controlled human studies demonstrate mostly additive CNS depression, with supra-additive (synergistic) responses in susceptible individuals without pharmacokinetic explanationsupported
Diazepam 5mg + alcohol interaction was mostly additive... in two subjects large supra-additive effects occurred at 3.5 h following alcohol+diazepam. pmid:7870919
Controlled human studies demonstrate mostly additive CNS depression, with supra-additive (synergistic) responses in susceptible individuals without pharmacokinetic explanationsupported
Diazepam showed only slight additive interactions with alcohol. pmid:3734141
Controlled human studies demonstrate mostly additive CNS depression, with supra-additive (synergistic) responses in susceptible individuals without pharmacokinetic explanationsupported
Effects of combined alcohol and diazepam were mostly additive without significant synergistic interactions. However, in two subjects large supra-additive effects occurred at 3.5 h following alcohol+diazepam. pmid:7870919
Claim in safety — not_supportednot supportedworking →
Multiple drugs alter diazepam metabolism via CYP2C19 and CYP3A4 inhibition:supported
CYP3A4 and 2C19 metabolize diazepam into the active metabolites: nordiazepam, temazepam and oxazepam. bku001
Concurrent opioid use without clinical monitoring: 10-fold mortality increase with co-administrationsupported
The mortality rate in co-administration of both medications is 10 times higher than those taking only opioids. pmid:33264528
Pregnancy (especially third trimester): floppy infant syndrome risksupported
Late third trimester exposure to diazepam associated with floppy infant syndrome. pmid:7881198
Breastfeeding: excreted in breast milk at low levelssupported
Diazepam excreted in breast milk. pmid:7881198
Claim in safety — inconclusiveinconclusiveworking →
Elderly patients (over 60 years): half-life extends to 80–100 hours; increased fall and cognitive impairment risksupported
can be increased to up to 80-100 h in subjects over 60 years of age. pmid:362051
CYP2C19 poor metabolizer status: significantly slower clearance; dose reduction may be requiredsupported
Approximately 2% of Europeans, 13% of East Asians, and as much as 57% of Oceanians have reduced or absent CYP2C19 enzyme activity. j.jphs.2014.12.006
neuroscience17 · 6 ok
Upon discontinuation, the reverse process — receptor upregulation and restored excitability — contributes to withdrawal syndrome severity.supported
GABAA receptor downregulation pathway: (1) desensitization, (2) sequestration/uncoupling, (3) subunit polypeptide degradation, (4) repression of subunit gene expression. Correlates with tolerance and physical dependence on benzodiazepines. pmid:8894844
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Individual vulnerability to dependence: CYP2C19 polymorphisms explain pharmacokinetic variability, but pharmacodynamic susceptibility to dependence — why some individuals develop severe dependence at therapeutic doses while others do not — is poorly characterized.supported
Approximately 2% of Europeans, 13% of East Asians, and as much as 57% of Oceanians have reduced or absent CYP2C19 enzyme activity. j.jphs.2014.12.006
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Receptor trafficking: Sustained diazepam exposure induces calcium influx through L-type voltage-gated calcium channels (L-VGCCs), triggering enhanced endocytosis and lysosomal targeting of surface α1-containing GABA-A receptors and uncoupling of GABA and benzodiazepine binding sites.supported
DZP treatment enhanced lysosomal targeting of surface GABAARs. Gephyrin and gamma2-GABAAR synaptic availability were reduced via multiple dynamic trafficking processes. fncel.2019.00163
Receptor trafficking: Sustained diazepam exposure induces calcium influx through L-type voltage-gated calcium channels (L-VGCCs), triggering enhanced endocytosis and lysosomal targeting of surface α1-containing GABA-A receptors and uncoupling of GABA and benzodiazepine binding sites.supported
Diazepam treatment induced uncoupling between GABA and benzodiazepine sites and produced selective transcriptional down-regulation of GABAA receptor alpha1 subunit gene through a mechanism dependent on L-type voltage-gated calcium channels. j.neulet.2020.134801
Transcriptional downregulation: Chronic exposure causes selective transcriptional suppression of the α1 subunit gene in frontal cortex, also via L-VGCC-dependent calcium signaling.supported
10-14 days treatment with increasing doses of diazepam resulted in anticonvulsant tolerance and decreased expression of the alpha1 GABAA receptor subunit mRNA and protein in frontal cortex. prp2.416
These mechanisms collectively reduce the population of functional benzodiazepine-sensitive receptors, explaining tolerance onset within 10–14 days of continuous exposuresupported
10-14 days treatment with increasing doses of diazepam resulted in anticonvulsant tolerance and decreased expression of the alpha1 GABAA receptor subunit mRNA and protein in frontal cortex. prp2.416
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
pharmacology17 · 11 ok
Claim in pharmacology — inconclusiveinconclusiveworking →
The existence of this specific, high-affinity benzodiazepine binding site was first demonstrated by Möhler and Okada in 1977, who showed that binding stereospecificity and competition rank order across benzodiazepines paralleled pharmacological potency — establishing this as the physiologically relevant target.supported
Diazepam, a potent minor tranquilizer, binds with high affinity to a specific benzodiazepine receptor that occurs exclusively in the central nervous system. Binding to the receptor is stereospecific. pmid:918669
At the molecular level, a halogen bond forms between diazepam's C7-chloro group and the backbone of histidine-102 (His102) on the α1 subunit, confirmed by cryo-EM structure analysis (PDB: 6HUP)partially supported
A halogen bond between the chlorine atoms of diazepam with the backbone of the alpha1 histidine amino acid 102 is important to its positive allosteric modulatory actions. j.bmcl.2022.128637
This histidine is the critical determinant of diazepam sensitivity: GABA-A receptors containing α4 or α6 subunits bear arginine rather than histidine at this position, rendering them diazepam-insensitivesupported
Alpha4 and alpha6 subunit-containing receptors are diazepam-insensitive due to a histidine-to-arginine substitution. pmid:16184188
Receptors containing α1, α2, α3, or α5 subunits all retain histidine and constitute the diazepam-sensitive population.supported
Non-selective benzodiazepines like diazepam interact with equivalent affinity at GABAA receptors containing alpha1, alpha2, alpha3 or alpha5 subunits. pmid:17092983
Receptors containing α1, α2, α3, or α5 subunits all retain histidine and constitute the diazepam-sensitive population.supported
Classical benzodiazepines bind to GABAA receptors containing alpha1, alpha2, alpha3 or alpha5 subunits. pmid:16184188
Diazepam binds all four sensitive subtypes with approximately equivalent affinity (Ki ≈ 6.4 nM), producing the full pharmacological spectrum at any therapeutic dose:supported
Non-selective benzodiazepines like diazepam interact with equivalent affinity at GABAA receptors containing alpha1, alpha2, alpha3 or alpha5 subunits. pmid:17092983
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
This non-selectivity is the central limitation of diazepam's therapeutic profile and the driver of research into subtype-selective benzodiazepine-site ligands for second-generation anxiolytics.supported
GABAA receptor subtype-selective modulators. I. alpha2/alpha3-selective agonists as non-sedating anxiolytics pmid:21050172
In vivo receptor occupancy data from PET studies in mice demonstrate that the oral dose occupying 50% of diazepam-sensitive GABA-A receptors is 1–2 mg/kg, independent of subtype, confirming high CNS penetration and efficacy at clinically relevant doses.supported
The dose to occupy 50% of sensitive receptors was 1-2 mg/kg, in agreement with published data from ex vivo studies with wild type mice. j.neuroimage.2017.02.022
Claim in pharmacology — inconclusiveinconclusiveworking →
The elimination half-life (t½β) is normally 24–48 hours but extends to 80–100 hours in subjects over 60 years of age and approximately doubles in hepatic disease.supported
The normal half-life (T1/2 beta) varies between 1 and 2 days, but can be increased to up to 80-100 h in subjects over 60 years of age. pmid:362051
Claim in pharmacology — inconclusiveinconclusiveworking →
Hepatic metabolism proceeds primarily via CYP2C19 (→ nordiazepam, the major active metabolite) and CYP3A4 (→ temazepam)supported
Temazepam formation was carried out mainly by CYP3A isoforms, whereas the formation of N-desmethyldiazepam was mediated by both CYP3A isoforms and S-mephenytoin hydroxylase (CYP2C19). pmid:7981013
Nordiazepam (t½ ≈ 51 hours) accumulates with repeated dosing because its elimination is slower than the parent compoundsupported
Major metabolite desmethyldiazepam: T1/2 51h. pmid:362051
summary13 · 9 ok
Claim in summary — inconclusiveinconclusiveworking →
Subjective effects persist 4–6 hours orally, but the parent compound's elimination half-life of 24–48 hours and its active metabolite nordiazepam (t½ ≈ 51 hours) sustain pharmacological activity well beyond subjective offset.supported
The normal half-life (T1/2 beta) varies between 1 and 2 days... Major metabolite desmethyldiazepam: T1/2 51h. pmid:362051
Claim in summary — inconclusiveinconclusiveworking →
The compound is the prototype for benzodiazepine pharmacology: Möhler and Okada's 1977 demonstration of specific, high-affinity CNS binding established the benzodiazepine receptor as a drug targetsupported
Diazepam, a potent minor tranquilizer, binds with high affinity to a specific benzodiazepine receptor that occurs exclusively in the central nervous system. pmid:918669
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
A halogen bond between the C7-chloro group and histidine-102 of sensitive α subunits is confirmed by cryo-EM; receptors bearing arginine at this position (α4, α6) are insensitivesupported
A halogen bond between the chlorine atoms of diazepam with the backbone of the alpha1 histidine amino acid 102 is important to its positive allosteric modulatory actions. j.bmcl.2022.128637
Non-selectivity across subtypes produces sedation, anxiolysis, anticonvulsant activity, and muscle relaxation simultaneously.supported
Non-selective benzodiazepines like diazepam interact with equivalent affinity at GABAA receptors containing alpha1, alpha2, alpha3 or alpha5 subunits. pmid:17092983
The experience is dominated by anxiolysis and sedation, with anterograde amnesia at common doses and psychomotor impairment comparable to alcohol at 0.8 g/kgsupported
Diazepam impaired tracking and body balance in addition to being sedative. Diazepam 10mg psychomotor impairment was comparable to alcohol 0.8g/kg. pmid:3734141
Individual response varies substantially with CYP2C19 metabolizer status, age, and prior exposure.supported
Approximately 2% of Europeans, 13% of East Asians, and as much as 57% of Oceanians have reduced or absent CYP2C19 enzyme activity. j.jphs.2014.12.006
Combined with opioids, mortality increases approximately tenfoldsupported
The mortality rate in co-administration of both medications is 10 times higher than those taking only opioids. pmid:33264528
Tolerance to sedative effects develops within days through convergent mechanisms: L-type calcium channel–mediated downregulation of α1-containing GABA-A receptors, transcriptional suppression of the α1 subunit gene, and epigenetic silencing via HDAC upregulationsupported
10-14 days treatment with increasing doses of diazepam resulted in anticonvulsant tolerance and decreased expression of the alpha1 GABAA receptor subunit mRNA and protein in frontal cortex. prp2.416
Physical dependence emerges even at therapeutic doses (10–20 mg/day) with sustained use; abrupt discontinuation can precipitate life-threatening withdrawal seizuressupported
Physical dependence is a risk associated with long-term use, even at therapeutic doses (10-20 mg of diazepam equivalent). pmid:1675689
clinical-evidence6 · 6 ok
In controlled studies, diazepam 10 mg produces psychomotor impairment equivalent to alcohol at 0.8 g/kg blood concentration, with significant impairment of tracking performance, body balance, and subjective sedation ratingssupported
Diazepam impaired tracking and body balance in addition to being sedative. Diazepam 10mg psychomotor impairment was comparable to alcohol 0.8g/kg. pmid:3734141
In a multicenter RCT (n = 326), flumazenil achieved successful reversal of benzodiazepine overdose in 77% of patients versus 16% with placebo, with a median reversal duration of approximately 90 minutessupported
Among benzodiazepine-positive patients, 77% given flumazenil vs 16% given placebo attained successful response. Median effect of flumazenil lasted 90 minutes. pmid:1286503
These data limit flumazenil's role to carefully selected cases of isolated benzodiazepine overdose in non-dependent patients.supported
Incremental intravenous bolus injections of flumazenil 0.1-0.3 mg are the most effective in diagnosis and treatment of pure benzodiazepine overdose. pmid:9306053
The anxiolytic efficacy of diazepam is primarily mediated through α2/α3-containing GABA-A receptors, while sedative effects arise predominantly through α1-containing receptorssupported
Alpha1-containing receptors mediate sedation; alpha2 and alpha3 mediate anxiolysis. pmid:21050172
Three FDA-approved rescue formulations exist for seizure cluster management: diazepam rectal gel (Diastat), diazepam nasal spray (Valtoco), and standard injectable formulationspartially supported
Three rescue therapies are approved in the United States for the treatment of seizure clusters: diazepam rectal gel, midazolam nasal spray, and diazepam nasal spray. j.ncl.2022.03.016
Controlled investigation of acute diazepam's amnestic effects demonstrated impairment of working memory capacity, increased susceptibility to retroactive interference, and accelerated forgetting — effects qualitatively similar to organic amnesiac syndromes.supported
Compared effects of diazepam with those reported in amnesiacs regarding working memory capacity, susceptibility to retroactive interference, and accelerated forgetting. hup.2774
receptor-pharmacology6 · 4 ok
PET imaging using [¹⁸F]flumazenil in mice confirms that diazepam occupies receptors across all brain regions containing sensitive subtypes at oral doses of 1–2 mg/kg (ED50 for 50% occupancy).supported
The dose to occupy 50% of sensitive receptors was 1-2 mg/kg, in agreement with published data from ex vivo studies with wild type mice. j.neuroimage.2017.02.022
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
The critical determinant of diazepam sensitivity is a single amino acid at position 101/102 of the α subunit: histidine in α1, α2, α3, and α5 (diazepam-sensitive) versus arginine in α4 and α6 (diazepam-insensitive).supported
Classical benzodiazepines bind to GABAA receptors containing alpha1, alpha2, alpha3 or alpha5 subunits. Alpha4 and alpha6 subunit-containing receptors are diazepam-insensitive due to a histidine-to-arginine substitution. pmid:16184188
Diazepam does not discriminate meaningfully between the four sensitive α subtypes — it binds α1, α2, α3, and α5 with approximately equivalent affinitysupported
Non-selective benzodiazepines like diazepam interact with equivalent affinity at GABAA receptors containing alpha1, alpha2, alpha3 or alpha5 subunits. pmid:17092983
The pharmacological effects segregate by α-subunit composition:supported
Alpha1-containing receptors mediate sedation; alpha2 and alpha3 mediate anxiolysis. pmid:21050172
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
history5 · 1 ok
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
The pivotal discovery came in 1977, when Möhler and Okada demonstrated that diazepam binds with high affinity to a specific receptor in the CNS, with stereospecific binding that correlated with pharmacological potency across the benzodiazepine classsupported
Diazepam, a potent minor tranquilizer, binds with high affinity to a specific benzodiazepine receptor that occurs exclusively in the central nervous system. Binding to the receptor is stereospecific. pmid:918669
pharmacokinetic-detail5 · 4 ok
Diazepam undergoes oxidative metabolism via two primary CYP pathways:supported
Diazepam is primarily metabolized by CYP3A4 and CYP2C19 to the major active metabolite, desmethyldiazepam. j.jphs.2014.12.006
Diazepam undergoes oxidative metabolism via two primary CYP pathways:supported
Temazepam formation was carried out mainly by CYP3A isoforms, whereas the formation of N-desmethyldiazepam was mediated by both CYP3A isoforms and S-mephenytoin hydroxylase (CYP2C19). pmid:7981013
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
In subjects over 60, the elimination half-life extends to 80–100 hourssupported
can be increased to up to 80-100 h in subjects over 60 years of age. pmid:362051
Inter-individual variability in diazepam clearance is largely attributable to CYP2C19 polymorphismssupported
Approximately 2% of Europeans, 13% of East Asians, and as much as 57% of Oceanians have reduced or absent CYP2C19 enzyme activity. j.jphs.2014.12.006
comparative-pharmacology4 · 3 ok
A key pharmacological distinction is diazepam's dependence on oxidative (Phase I) metabolism via CYP2C19 and CYP3A4, which generates active metabolites and is vulnerable to hepatic impairment, drug interactions, and genetic polymorphismsupported
Diazepam is primarily metabolized by CYP3A4 and CYP2C19 to the major active metabolite, desmethyldiazepam. Approximately 2% of Europeans, 13% of East Asians, and as much as 57% of Oceanians have reduced or absent CYP2C19 enzyme activity. j.jphs.2014.12.006
The ongoing development of α2/α3-selective PAMs aims to isolate anxiolytic effects from the sedation, amnesia, and dependence liability attributed to α1 and α5 activation.supported
GABAA receptor subtype-selective modulators. I. alpha2/alpha3-selective agonists as non-sedating anxiolytics. pmid:21050172
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Diazepam's combination of a long parent half-life (24–48 hours) and a longer-lived active metabolite (nordiazepam, t½ ≈ 51 hours) creates a stacking pharmacokinetic profile with repeated dosingsupported
The normal half-life (T1/2 beta) varies between 1 and 2 days... Major metabolite desmethyldiazepam: T1/2 51h. pmid:362051